MHC-HM415B-100μg / 询价
MHC-HM415B-500μg / 询价
MHC-HM415B-500μgx2 / 询价
- 客服电话
- 技术支持
Biotinylated Human HLA-A*02:01&B2M&P53 R175H (HMTEVVRHC) Monomer Protein
Recombinant Biotinylated Human HLA-A*02:01&B2M&P53 R175H (HMTEVVRHC) Monomer Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus.It contains Gly25-Thr305 (HLA-A*02:01), Ile21-Met119 (B2M) and HMTEVVRHC peptide [Accession | A0A140T913(HLA-A*02:01)&P61769(B2M)&HMTEVVRHC].
The protein has a predicted MW of 50.5 kDa. Due to glycosylation, the protein migrates to 55-60 kDa based on Bis-Tris PAGE result.
> 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC
Less than 1EU per μg by the LAL method.
Supplied as 0.22μm filtered solution in 20mM Tris, 150mM NaCl, 100mM L-Arginine (pH 8.0).
Valid for 12 months from date of receipt when stored at -80°C.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Biotinylated Human HLA-A*02:01&B2M&P53 R175H (HMTEVVRHC) Monomer on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Biotinylated Human HLA-A*02:01&B2M&P53 R175H (HMTEVVRHC) Monomer was greater than 95% as determined by SEC-HPLC.
Immobilized Anti-HLA-A*02:01&B2M&P53 R175H (HMTEVVRHC) Antibody, hFc Tag at 5μg/ml (100μl/well) on the plate. Dose response curve for Biotinylated Human HLA-A*02:01&B2M&P53 R175H (HMTEVVRHC) Monomer, His Tag with the EC50 of 0.25μg/ml determined by ELISA.
p53 is a tumor suppressor protein. Under stressful conditions, p53 tightly regulates cell growth by promoting apoptosis and DNA repair. When p53 becomes mutated, it loses its function, resulting in abnormal cell proliferation and tumor progression. Depending on the p53 mutation, it has been shown to form aggregates leading to negative gain of function of the protein.p53 mutant associated aggregation has been observed in several cancer tissues and has been shown to promote tumor growth.
MHC; HLA-A; P53; TP53; Antigen NY-CO-13; BCC7; FLJ92943; LFS1; TRP53
(1) Kanapathipillai M. Treating p53 Mutant Aggregation-Associated Cancer. Cancers (Basel). 2018 May 23;10(6):154. doi: 10.3390/cancers10060154. PMID: 29789497; PMCID: PMC6025594.
